American biotechnology company Moderna announced that it was preparing for the global launch of its Covid-19 vaccine candidate.
“We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world,” Xinhua news agency quoted Moderna CEO Stephane Bancel as saying in a statement on Thursday.
In addition to the Phase-3 study of the COVID-19 vaccine mRNA-1273, which is fully enrolled, Moderna now has four programs in Phase-2 studies, according to Bancel.
On 22 October, the Phase 3 study of mRNA-1273 completed enrollment of 30,000 participants with approximately 37 per cent of participants from diverse communities.
The Phase-1 interim analysis of the vaccine, published in The New England Journal of Medicine on 14 July, showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2.
